**Kerrin Rennie Award for**

**Excellence in Medical Technology and Improving Quality of Life**

**2020 Rules and Criteria**

The Medical Technology Association of Australia (MTAA) invites the Australian medical technology industry to participate in the ***2020 Kerrin Rennie Award for Excellence in Medical Technology and Improving Quality of Life.***

This award recognises the innovative and extraordinary contribution of medical technology in improving health outcomes for Australian patients.

Any medical technology company based in or represented in Australia may enter a product launched in Australia between **1 January 2015 and 30 June 2020** and used in the diagnosis, prevention or treatment of disease or disability or improvement of quality of life.

Entry is not limited only to the members of MTAA.

**2020** **Key Dates**

**4 September:** Nominations Open

**22 October:** Nominations Closed

**17 November:** Winners announced at MTAA Annual General Meeting

**How to enter:**

* Complete the attached nomination form
* Address the criteria and include an executive summary as set out in the rules
* Include any supporting documentation as set out in the rules
* Send your confidential application electronically, **by COB Thursday, 22 October 2020** to secretary@mtaa.org.au

**Criteria:**

The product must demonstrate the following criteria:

* Evidence of significant contribution to improving patient outcomes by improving quality of life
* Evidence of technical excellence
* Evidence of innovation

In addressing the criteria applicants should consider and address the following questions:

* What health problem is the technology addressing and how does it address it?
* What other products are currently available to address this issue and how does this technology differ from existing technology?
* Describe the technology
* Having regard to the consumer’s quality of life, does the product provide a balance between invasiveness and efficacy?
* Scientific evidence to support the claims against the criteria. This may include published data, unpublished scientific data, results of clinical trials and/or patient feedback

**Rules:**

* Entries will be accepted from any medical technology company based in Australia or represented in Australia at the time of product launch
* A company may enter more than one product. Each product will require a separate application
* Applications which do not address the criteria will not be considered
* No more than three applications will be accepted from any one company
* A product must include medical technology used in the diagnosis, prevention or treatment of disease or disability or improvement of quality of life
* The product must be launched in Australia between **1 January 2015 and 30 June 2020**
* Product must have either been designed, manufactured or distributed in Australia
* Entries must be sent electronically to MTAA
* Entries must include an executive summary of no more than 200 words which is suitable for use in future promotion
* Entries must address the criteria and each response to the criteria must be no more than 300 words in length
* Applicants must complete an entry form signed by the company CEO or an authorised company representative.
* Entries may include photographs, supporting documentation and or samples
* Entrants must be willing to participate in promotional activities relating to the Award
* The decision of the judging panel is final and no further correspondence about the decision of the judging panel will be entered

**Judges:**

The judging panel is independent of MTAA. It consists of a maximum of five individuals from around Australia, each of whom is selected for their expertise in medical technology, academia and research or represents a health professional or consumer perspective.

**Timeline:**

Nomination must be received at MTAA Secretariat by **COB Friday, 22 October 2020.**

The winner will be announced at the MTAA Annual General Meeting in Sydney on **Tuesday, 17 November 2020**

# Section 1: Application Summary

|  |  |
| --- | --- |
| Name of Product |  |
| Australian launch date |  |
| Products used in (please select) | ✔diagnosis ✔ prevention ✔ treatment ✔ management |
| Contact details |  |

**Your details**

|  |  |  |  |
| --- | --- | --- | --- |
| Name |  | Position |  |
| Email |  | Phone |  |
| Name of Company |  | ABN |  |

|  |
| --- |
| Executive Summary: [200 words max.] NB Executive Summary must be suitable for use in Award promotion |
|  |

# Section 2: Product Details

|  |
| --- |
| Describe the technology [300 words max.] |
|  |

|  |
| --- |
| What health problem is the technology addressing and how does it address the problem? [300 words max.] |
|  |

|  |
| --- |
| What other products are currently available to address this issue and how does this technology differ from and/or improve on existing technology? [300 words max.]Medical Technology Association of Australia Limited ABN 61 129 334 354 |
|  |

|  |
| --- |
| Having regard to the consumer’s quality of life, does the product provide a balance between invasiveness and efficacy? [300 words max.] |
|  |

|  |
| --- |
| Include scientific evidence to support the claims. This may include published data, unpublished scientific data, results of clinical trials and/or patient feedback. Photographs may be submitted. Product samples will not be accepted. |
|  |

# Section 3: Declaration

*I certify that the information provided in this application is accurate and that the company accepts the Rules of the Award. Representative/s of the company will participate in promotional activities relating to the Award.*

*Name: \_ Position:*

*Signature of the CEO/Authorised Representative:*

*Date:* / / \_

*Please send your application to secretary@mtaa.org.au – Kerrin Rennie Award*

 CLOSING DATE: **22 October 2020**